TY - JOUR
T1 - Characterization of ADME gene variation in 21 populations by exome sequencing
AU - Hovelson, Daniel H.
AU - Xue, Zhengyu
AU - Zawistowski, Matthew
AU - Ehm, Margaret G.
AU - Harris, Elizabeth C.
AU - Stocker, Sophie L.
AU - Gross, Annette S.
AU - Jang, In Jin
AU - Ieiri, Ichiro
AU - Lee, Jong Eun
AU - Cardon, Lon R.
AU - Chissoe, Stephanie L.
AU - Abecasis, Gonçalo
AU - Nelson, Matthew R.
N1 - Funding Information:
This study was supported by GlaxoSmithKline (GSK). The authors, Zhengyu Xue, Elizabeth C. Harris, and Sophie L. Stocker, were previously employed by GSK and hold GSK stocks, and the research for this publication was performed while they were employed by GSK; the authors, Margaret G. Ehm, Annette S. Gross, Lon R. Cardon, Stephanie L. Chissoe, and Matthew R. Nelson, have an employment or leadership position with GlaxoSmithKline and hold GSK stocks. Gonçalo Abecasis received GSK research grants. For the remaining authors there are no conflicts of interest.
Publisher Copyright:
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2017
Y1 - 2017
N2 - Objective Proteins involving absorption, distribution, metabolism, and excretion (ADME) play a critical role in drug pharmacokinetics. The type and frequency of genetic variation in the ADME genes differ among populations. The aim of this study was to systematically investigate common and rare ADME coding variation in diverse ethnic populations by exome sequencing. Materials and methods Data derived from commercial exome capture arrays and next-generation sequencing were used to characterize coding variation in 298 ADME genes in 251 Northeast Asians and 1181 individuals from the 1000 Genomes Project. Results Approximately 75% of the ADME coding sequence was captured at high quality across the joint samples harboring more than 8000 variants, with 49% of individuals carrying at least one 'knockout' allele. ADME genes carried 50% more nonsynonymous variation than non-ADME genes (P=8.2×10-13) and showed significantly greater levels of population differentiation (P=7.6×10-11). Out of the 2135 variants identified that were predicted to be deleterious, 633 were not on commercially available ADME or general-purpose genotyping arrays. Forty deleterious variants within important ADME genes, with frequencies of at least 2% in at least one population, were identified as candidates for future pharmacogenetic studies. Conclusion Exome sequencing was effective in accurately genotyping most ADME variants important for pharmacogenetic research, in addition to identifying rare or potentially de novo coding variants that may be clinically meaningful. Furthermore, as a class, ADME genes are more variable and less sensitive to purifying selection than non-ADME genes.
AB - Objective Proteins involving absorption, distribution, metabolism, and excretion (ADME) play a critical role in drug pharmacokinetics. The type and frequency of genetic variation in the ADME genes differ among populations. The aim of this study was to systematically investigate common and rare ADME coding variation in diverse ethnic populations by exome sequencing. Materials and methods Data derived from commercial exome capture arrays and next-generation sequencing were used to characterize coding variation in 298 ADME genes in 251 Northeast Asians and 1181 individuals from the 1000 Genomes Project. Results Approximately 75% of the ADME coding sequence was captured at high quality across the joint samples harboring more than 8000 variants, with 49% of individuals carrying at least one 'knockout' allele. ADME genes carried 50% more nonsynonymous variation than non-ADME genes (P=8.2×10-13) and showed significantly greater levels of population differentiation (P=7.6×10-11). Out of the 2135 variants identified that were predicted to be deleterious, 633 were not on commercially available ADME or general-purpose genotyping arrays. Forty deleterious variants within important ADME genes, with frequencies of at least 2% in at least one population, were identified as candidates for future pharmacogenetic studies. Conclusion Exome sequencing was effective in accurately genotyping most ADME variants important for pharmacogenetic research, in addition to identifying rare or potentially de novo coding variants that may be clinically meaningful. Furthermore, as a class, ADME genes are more variable and less sensitive to purifying selection than non-ADME genes.
UR - http://www.scopus.com/inward/record.url?scp=85011371184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011371184&partnerID=8YFLogxK
U2 - 10.1097/FPC.0000000000000260
DO - 10.1097/FPC.0000000000000260
M3 - Article
C2 - 27984508
AN - SCOPUS:85011371184
SN - 1744-6872
VL - 27
SP - 89
EP - 100
JO - Pharmacogenetics
JF - Pharmacogenetics
IS - 3
ER -